Azora Therapeutics, Inc. (DE) ADIL

Adial Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead investigational drug candidate AD04 contains ondansetron and is being developed for alcohol use disorder. The company conducts clinical trials seeks regulatory approval and protects its intellectual property.

Adial Pharmaceuticals Inc does not have any products approved for sale and has not generated significant revenue since its inception. Funding for operations comes from private and public placements of debt equity securities and an equity line. The company expects to generate revenue from product sales only after obtaining marketing approval for AD04. Potential revenue sources also include upfront payments milestone payments and royalties from collaboration agreements such as the framework agreement with Molteni Farmaceutici for the commercialization of AD04 in Europe.

Adial Pharmaceuticals Inc operates in the biopharmaceutical industry with a focus on addiction therapeutics. It competes with manufacturers of existing FDA approved medications for alcohol use disorder such as disulfiram naltrexone acamprosate and nalmefene. The company differentiates itself through its companion diagnostic genetic test that identifies patients likely to respond to AD04. Adial holds a worldwide exclusive license to multiple patent families from the University of Virginia Patent Foundation providing protection through at least 2031 with a pending application that could extend protection to 2045. Its low dose ondansetron formulation and harm reduction approach aim to address limitations of current abstinence based therapies.

Adial Pharmaceuticals Inc serves patients diagnosed with alcohol use disorder who possess the specific genetic biomarkers targeted by its companion diagnostic. The company also works with healthcare providers including addiction specialists psychiatrists and primary care physicians who may prescribe AD04 after genetic testing. No specific customer names are disclosed in the filing.